 AIM ImmunoTech Inc announced it had submitted a pre-investigational New Drug application pre-IND to the US Food and Drug Administration FDA for two separate Phase 2 clinical studies to study Ampligen as both an infusion and an intranasal therapy for early-onset coronavirus COVID-19. With Ampligens recently established intranasal safety profile, and the preliminary results from these trials, we may be able to show that Ampligen not only has an early-onset therapeutic effect against a broad spectrum of respiratory viruses, but also may provide a boost to post-infection immunity that will confer cross-protection against viral variants, AIM CEO Thomas K. 